INmune Bio (NASDAQ:INMB) used a company webcast to highlight updates from its Mission EB phase III clinical trial evaluating CORDStrom, an intravenous mesenchymal stromal cell (MSC) therapy, in children with recessive dystrophic epidermolysis bullosa (RDEB). CEO David Moss said the presentation would focus on “pivotal updates” from Mission EB and the potential of CORDStrom to […]